Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01908829




Registration number
NCT01908829
Ethics application status
Date submitted
24/07/2013
Date registered
26/07/2013
Date last updated
31/10/2024

Titles & IDs
Public title
A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)
Scientific title
A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms
Secondary ID [1] 0 0
2012-005401-41
Secondary ID [2] 0 0
905-EC-012
Universal Trial Number (UTN)
Trial acronym
BESIDE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Urinary Bladder Diseases 0 0
Urinary Bladder Overactive 0 0
Urologic Diseases 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - mirabegron 25 mg
Treatment: Drugs - mirabegron 50 mg
Treatment: Drugs - solifenacin 5 mg
Treatment: Drugs - solifenacin 10 mg
Treatment: Drugs - mirabegron 25 mg matching placebo
Treatment: Drugs - mirabegron 50 mg matching placebo
Treatment: Drugs - solifenacin 5 mg matching placebo
Treatment: Drugs - solifenacin 10 mg matching placebo

Experimental: Combination (solifenacin + mirabegron) - Participants received solifenacin 5 mg, mirabegron 25 mg and solifenacin 10 mg matching placebo once daily for the first 4 weeks of double-blind period. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron tablet was replaced by a 50 mg mirabegron tablet. Placebo was given for the 2 week single-blind safety follow-up period.

Active comparator: Solifenacin 5 mg - Participants received solifenacin 5 mg, mirabegron 25 mg matching placebo and solifenacin 10 mg matching placebo once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period

Active comparator: Solifenacin 10 mg - Participants received solifenacin 5 mg matching placebo, mirabegron 25 mg matching placebo and solifenacin 10 mg once daily. For the last 8 weeks of the double-blind treatment period, the 25 mg mirabegron matching placebo tablet was replaced by a 50 mg mirabegron matching placebo tablet (to maintain the blind). Placebo was given for the 2 week single-blind safety follow-up period.


Treatment: Drugs: mirabegron 25 mg
Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.

Treatment: Drugs: mirabegron 50 mg
Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.

Treatment: Drugs: solifenacin 5 mg
Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.

Treatment: Drugs: solifenacin 10 mg
Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.

Treatment: Drugs: mirabegron 25 mg matching placebo
Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Treatment: Drugs: mirabegron 50 mg matching placebo
Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Treatment: Drugs: solifenacin 5 mg matching placebo
Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.

Treatment: Drugs: solifenacin 10 mg matching placebo
Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline to End of Treatment (EoT) in Mean Number of Incontinence Episodes Per 24 Hours
Timepoint [1] 0 0
Baseline and end of treatment (up to 12 weeks)
Secondary outcome [1] 0 0
Change From Baseline to Weeks 4, 8 & 12 in Mean Number of Incontinence Episodes Per 24 Hours
Timepoint [1] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [2] 0 0
Change From Baseline in Mean Number of Micturitions Per 24 Hours
Timepoint [2] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [3] 0 0
Number of Incontinence Episodes Reported During the 3-Day Diary
Timepoint [3] 0 0
Weeks 4, 8 and 12
Secondary outcome [4] 0 0
Change From Baseline in Mean Volume Voided (MVV) Per Micturition
Timepoint [4] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [5] 0 0
Change From Baseline to EoT in Corrected Micturition Frequency (CMF)
Timepoint [5] 0 0
Baseline and EoT (up to 12 weeks)
Secondary outcome [6] 0 0
Change From Baseline in Mean Number of Urgency Incontinence (UI) Episodes Per 24 Hours
Timepoint [6] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [7] 0 0
Number of UI Episodes Reported During the 3-Day Diary
Timepoint [7] 0 0
Weeks 4, 8 and 12
Secondary outcome [8] 0 0
Change From Baseline in Mean Number of Urgency Episodes (Grade 3 and/or 4) Per 24 Hours
Timepoint [8] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [9] 0 0
Change From Baseline in Mean Number of Pads Per 24 Hours
Timepoint [9] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [10] 0 0
Number of Pads Used During the 3-Day Diary
Timepoint [10] 0 0
Weeks 4, 8 and 12
Secondary outcome [11] 0 0
Change From Baseline in Mean Number of Nocturia Episodes
Timepoint [11] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [12] 0 0
Number of Nocturia Episodes Reported Over 3-Day Diary
Timepoint [12] 0 0
Weeks 4, 8 and 12
Secondary outcome [13] 0 0
Number of Participants With Change From Baseline to EoT in Euroqol European Quality of Life-5 Dimensions (EQ-5D) Subscale Score: Mobility
Timepoint [13] 0 0
Baseline and EoT (up to 12 weeks)
Secondary outcome [14] 0 0
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Self-care
Timepoint [14] 0 0
Baseline and EoT (up to 12 weeks)
Secondary outcome [15] 0 0
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Usual Activities
Timepoint [15] 0 0
Baseline and EoT (up to 12 weeks)
Secondary outcome [16] 0 0
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Pain/Discomfort
Timepoint [16] 0 0
Baseline and EoT (up to 12 weeks)
Secondary outcome [17] 0 0
Number of Participants With Change From Baseline to EoT in EQ-5D Subscale Score: Anxiety/Depression
Timepoint [17] 0 0
Baseline and EoT (up to 12 weeks)
Secondary outcome [18] 0 0
Change From Baseline in Overactive Bladder Symptom (OAB-q) Symptom Bother Score
Timepoint [18] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [19] 0 0
Change From Baseline in OAB-q Health-Related Quality of Life (HRQL) Total Score
Timepoint [19] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [20] 0 0
Change From Baseline in OAB-q HRQL Subscale Score: Coping
Timepoint [20] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [21] 0 0
Change From Baseline in OAB-q HRQL Subscale Score: Concern
Timepoint [21] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [22] 0 0
Change From Baseline in OAB-q HRQL Subscale Score: Sleep
Timepoint [22] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [23] 0 0
Change From Baseline in OAB-q HRQL Subscale Score: Social Interaction
Timepoint [23] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [24] 0 0
Change From Baseline in Treatment Satisfaction - Visual Analogue Scale (TS-VAS) Score
Timepoint [24] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [25] 0 0
Change From Baseline in Patient Perception Bladder Control (PPBC) Score
Timepoint [25] 0 0
Baseline and weeks 4, 8 & 12
Secondary outcome [26] 0 0
Number of Participants in Each Category of Patient and Clinician Global Impression of Change Scales (PGIC and CGIC)
Timepoint [26] 0 0
End of treatment (up to 12 weeks)
Secondary outcome [27] 0 0
Percentage of Participants With at Least a 50% Decrease From Baseline in Mean Number of Incontinence Episodes Per 24 Hours
Timepoint [27] 0 0
Weeks 4, 8 and 12
Secondary outcome [28] 0 0
Percentage of Participants With Zero Incontinence Episodes Postbaseline
Timepoint [28] 0 0
Weeks 4, 8 and 12
Secondary outcome [29] 0 0
Percentage of Participants With a Mean of at Least 8 Micturitions Per 24 Hours at Baseline and Less Than 8 Micturitions Per 24 Hours Postbaseline
Timepoint [29] 0 0
Weeks 4, 8 and 12
Secondary outcome [30] 0 0
Percentage of Participants With at Least a 10-Point Improvement From Baseline in OAB-q Symptom Bother Score
Timepoint [30] 0 0
Weeks 4, 8 and 12
Secondary outcome [31] 0 0
Percentage of Participants With at Least a 10-Point Improvement From Baseline in HRQL Total Score
Timepoint [31] 0 0
Weeks 4, 8 and 12
Secondary outcome [32] 0 0
Percentage of Participants With at Least a 1-Point Improvement From Baseline in PPBC
Timepoint [32] 0 0
Weeks 4, 8 and 12
Secondary outcome [33] 0 0
Percentage of Participants With Major (at Least 2-Point) Improvement From Baseline in PPBC
Timepoint [33] 0 0
Weeks 4, 8 and 12
Secondary outcome [34] 0 0
Number of Participants With Adverse Events (AEs)
Timepoint [34] 0 0
From first dose of double blind treatment until 30 days after last dose (up to 16 weeks)
Secondary outcome [35] 0 0
Change From Baseline in Post Void Residual (PVR) Volume
Timepoint [35] 0 0
Baseline and weeks 4, 8 & 12

Eligibility
Key inclusion criteria
* Main Inclusion at Screening:

1. Subject has symptoms of OAB (urinary frequency and urgency with urgency incontinence) for >= 3 months prior to the screening visit
2. Subject is willing and able to complete the micturition diary and questionnaires correctly, including collection and measurement of urine output for 3 days prior to each visit;
3. Subject has symptoms of "wet" OAB (urinary frequency and urgency with incontinence or mixed incontinence with predominant urgency incontinence), and reports an average of at least 2 incontinence episodes per day.
* Main Inclusion at Run-in (Visit 2):

1. Subject experiences on average at least 1 episode of urgency (grade 3 or 4) with or without incontinence per 24-hour period during the 3-day micturition diary period.
2. Subject experiences on average at least 2 incontinence episodes per 24-hour period during the 3-day micturition diary period.
3. Subject experiences on average at least 8 micturitions (excluding incontinence episodes) per 24-hour period during the 3-day micturition diary period.
* Main Inclusion at Randomization (Visit 3):

1. Subject experiences at least 1 incontinence episode during the 3-day micturition diary period and wishes to increase their treatment for OAB symptoms.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Main Exclusion at Screening:

1. Subject in the opinion of the investigator has clinically significant Bladder Outlet Obstruction (BOO).
2. Subject has significant Post-void residual (PVR) volume (PVR > 150 ml).
3. Subject has significant stress incontinence or mixed stress/urgency incontinence where stress is the predominant factor as determined by the investigator
4. Subject has an indwelling catheter or practices intermittent self catheterization.
5. Subject has evidence of a UTI.
6. Subject has chronic inflammation such as interstitial cystitis, bladder stones, previous pelvic radiation therapy, or previous or current malignant disease of the pelvic organs
7. Subject has moderate to severe hepatic impairment
8. Subject has severe renal impairment or End Stage Renal disease
9. Subject has a clinically significant abnormal Electrocardiogram (ECG)
10. Subject has a concurrent malignancy or history of cancer (except noninvasive skin cancer) within the last 5 years prior to screening.
11. Subject has a QTcF interval > 450 ms for males or > 470 ms for females or is at risk of QT prolongation (e.g., family history of long QT syndrome, hypokalaemia).
12. Subject has received intravesical treatment in the past 12 months with e.g., botulinum toxin, resiniferatoxin, capsaicin.
13. Subject has severe uncontrolled hypertension, which is defined as a sitting average systolic blood pressure = 180 mmHg and/or average diastolic blood pressure = 110 mmHg.
* Main Exclusion at Randomization (visit 3):

1. Subject has achieved 100% continence from Visit 2 to Visit 3 (no incontinence episodes are recorded in the 3 day diary administered for 3 days prior to Visit 3).
2. Subject does not desire an increase in study medication.
3. Subject has an average total daily urine volume > 3000ml as recorded in the micturition diary.
4. Subject has severe uncontrolled hypertension, which is defined as a sitting average systolic blood pressure = 180 mmHg and/or average diastolic blood pressure = 110 mmHg.
5. Subject has a clinically significant abnormal ECG

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
10/07/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/11/2014
Sample size
Target
Accrual to date
Final
2174
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Site: 61006 - Adelaide
Recruitment hospital [2] 0 0
Site: 61001 - Kogarah, Sydney
Recruitment hospital [3] 0 0
Site: 61016 - Victoria
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Kogarah, Sydney
Recruitment postcode(s) [3] 0 0
- Victoria
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Idaho
Country [6] 0 0
United States of America
State/province [6] 0 0
Indiana
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Nebraska
Country [11] 0 0
United States of America
State/province [11] 0 0
New Mexico
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Pennsylvania
Country [16] 0 0
United States of America
State/province [16] 0 0
South Dakota
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah
Country [18] 0 0
United States of America
State/province [18] 0 0
Virginia
Country [19] 0 0
Armenia
State/province [19] 0 0
Yerevan
Country [20] 0 0
Austria
State/province [20] 0 0
Graz
Country [21] 0 0
Austria
State/province [21] 0 0
Innsbruck
Country [22] 0 0
Austria
State/province [22] 0 0
Linz
Country [23] 0 0
Austria
State/province [23] 0 0
Vienna
Country [24] 0 0
Austria
State/province [24] 0 0
Wels
Country [25] 0 0
Belgium
State/province [25] 0 0
Anderlecht
Country [26] 0 0
Belgium
State/province [26] 0 0
Deurne
Country [27] 0 0
Belgium
State/province [27] 0 0
Edegem
Country [28] 0 0
Belgium
State/province [28] 0 0
Gent
Country [29] 0 0
Belgium
State/province [29] 0 0
Kortrijk
Country [30] 0 0
Belgium
State/province [30] 0 0
Liege
Country [31] 0 0
Belgium
State/province [31] 0 0
Roeselare
Country [32] 0 0
Canada
State/province [32] 0 0
Barrie
Country [33] 0 0
Canada
State/province [33] 0 0
Bathurst
Country [34] 0 0
Canada
State/province [34] 0 0
Brampton
Country [35] 0 0
Canada
State/province [35] 0 0
Granby
Country [36] 0 0
Canada
State/province [36] 0 0
Kelowna
Country [37] 0 0
Canada
State/province [37] 0 0
Kitchener
Country [38] 0 0
Canada
State/province [38] 0 0
Sherbrooke
Country [39] 0 0
Canada
State/province [39] 0 0
Toronto
Country [40] 0 0
Canada
State/province [40] 0 0
Victoriaville
Country [41] 0 0
Canada
State/province [41] 0 0
Victoria
Country [42] 0 0
Czechia
State/province [42] 0 0
Brno
Country [43] 0 0
Czechia
State/province [43] 0 0
Melnik
Country [44] 0 0
Czechia
State/province [44] 0 0
Nachod
Country [45] 0 0
Czechia
State/province [45] 0 0
Plzen
Country [46] 0 0
Czechia
State/province [46] 0 0
Prague 1
Country [47] 0 0
Czechia
State/province [47] 0 0
Prague
Country [48] 0 0
Czechia
State/province [48] 0 0
Praha 2
Country [49] 0 0
Czechia
State/province [49] 0 0
Praha 4
Country [50] 0 0
Denmark
State/province [50] 0 0
Aarhus N
Country [51] 0 0
Denmark
State/province [51] 0 0
Frederiksberg
Country [52] 0 0
Denmark
State/province [52] 0 0
Herlev
Country [53] 0 0
Denmark
State/province [53] 0 0
Odense C
Country [54] 0 0
Finland
State/province [54] 0 0
Helsinki (hus)
Country [55] 0 0
Finland
State/province [55] 0 0
Tampere
Country [56] 0 0
France
State/province [56] 0 0
Bordeaux Cedex
Country [57] 0 0
France
State/province [57] 0 0
Marseille
Country [58] 0 0
Georgia
State/province [58] 0 0
T'bilisi
Country [59] 0 0
Germany
State/province [59] 0 0
Bad Ems
Country [60] 0 0
Germany
State/province [60] 0 0
Berlin
Country [61] 0 0
Germany
State/province [61] 0 0
Hagenow
Country [62] 0 0
Germany
State/province [62] 0 0
Halle (Saale)
Country [63] 0 0
Germany
State/province [63] 0 0
Hamburg
Country [64] 0 0
Germany
State/province [64] 0 0
Henningsdorf
Country [65] 0 0
Germany
State/province [65] 0 0
Hettstedt
Country [66] 0 0
Germany
State/province [66] 0 0
Koblenz
Country [67] 0 0
Germany
State/province [67] 0 0
Lutherstadt Eisleben
Country [68] 0 0
Germany
State/province [68] 0 0
Reutlingen
Country [69] 0 0
Germany
State/province [69] 0 0
Sangerhausen
Country [70] 0 0
Greece
State/province [70] 0 0
Athens
Country [71] 0 0
Greece
State/province [71] 0 0
Heraklion, Crete
Country [72] 0 0
Greece
State/province [72] 0 0
Patras
Country [73] 0 0
Hungary
State/province [73] 0 0
Csongrad
Country [74] 0 0
Hungary
State/province [74] 0 0
Hajduszoboszlo
Country [75] 0 0
Hungary
State/province [75] 0 0
Nyiregyhaza
Country [76] 0 0
Hungary
State/province [76] 0 0
Salgotarjan
Country [77] 0 0
Hungary
State/province [77] 0 0
Szekszard
Country [78] 0 0
Ireland
State/province [78] 0 0
Cork
Country [79] 0 0
Ireland
State/province [79] 0 0
Dublin
Country [80] 0 0
Ireland
State/province [80] 0 0
Limerick
Country [81] 0 0
Ireland
State/province [81] 0 0
Mullingar
Country [82] 0 0
Ireland
State/province [82] 0 0
Tralee
Country [83] 0 0
Ireland
State/province [83] 0 0
Waterford
Country [84] 0 0
Israel
State/province [84] 0 0
Haifa
Country [85] 0 0
Israel
State/province [85] 0 0
Jerusalem
Country [86] 0 0
Israel
State/province [86] 0 0
Kfar Saba
Country [87] 0 0
Israel
State/province [87] 0 0
Petach Tikva
Country [88] 0 0
Israel
State/province [88] 0 0
Tel Hashomer
Country [89] 0 0
Italy
State/province [89] 0 0
Avellino
Country [90] 0 0
Italy
State/province [90] 0 0
Cantanzaro
Country [91] 0 0
Italy
State/province [91] 0 0
Firenze
Country [92] 0 0
Italy
State/province [92] 0 0
Perugia
Country [93] 0 0
Italy
State/province [93] 0 0
Treviglio (BG)
Country [94] 0 0
Italy
State/province [94] 0 0
Varese
Country [95] 0 0
Lebanon
State/province [95] 0 0
Beirut
Country [96] 0 0
Netherlands
State/province [96] 0 0
Amsterdam
Country [97] 0 0
Norway
State/province [97] 0 0
Bekkestua
Country [98] 0 0
Norway
State/province [98] 0 0
Tonsberg
Country [99] 0 0
Norway
State/province [99] 0 0
Trondheim
Country [100] 0 0
Poland
State/province [100] 0 0
Kolbuszowa Dolna
Country [101] 0 0
Poland
State/province [101] 0 0
Krakow
Country [102] 0 0
Poland
State/province [102] 0 0
Lublin
Country [103] 0 0
Poland
State/province [103] 0 0
Piaseczno
Country [104] 0 0
Poland
State/province [104] 0 0
Warszawa
Country [105] 0 0
Portugal
State/province [105] 0 0
Lisbon
Country [106] 0 0
Portugal
State/province [106] 0 0
Matosinhos
Country [107] 0 0
Portugal
State/province [107] 0 0
Porto
Country [108] 0 0
Portugal
State/province [108] 0 0
Setubal
Country [109] 0 0
Portugal
State/province [109] 0 0
Tomar
Country [110] 0 0
Romania
State/province [110] 0 0
Bucharest
Country [111] 0 0
Romania
State/province [111] 0 0
Craiova
Country [112] 0 0
Romania
State/province [112] 0 0
Judetul Ilfov
Country [113] 0 0
Romania
State/province [113] 0 0
Oradea
Country [114] 0 0
Romania
State/province [114] 0 0
Timisoara
Country [115] 0 0
Russian Federation
State/province [115] 0 0
Moscow
Country [116] 0 0
Russian Federation
State/province [116] 0 0
Rostove-on-Don
Country [117] 0 0
Russian Federation
State/province [117] 0 0
Saint Petersburg
Country [118] 0 0
Russian Federation
State/province [118] 0 0
Saratov
Country [119] 0 0
Slovakia
State/province [119] 0 0
Bratislava
Country [120] 0 0
Slovakia
State/province [120] 0 0
Kosice
Country [121] 0 0
Slovakia
State/province [121] 0 0
Michalovce
Country [122] 0 0
Slovakia
State/province [122] 0 0
Nove Zamky
Country [123] 0 0
Slovakia
State/province [123] 0 0
Piestany
Country [124] 0 0
Slovakia
State/province [124] 0 0
Poprad
Country [125] 0 0
Slovakia
State/province [125] 0 0
Zilina
Country [126] 0 0
Slovenia
State/province [126] 0 0
Ljubljana
Country [127] 0 0
Slovenia
State/province [127] 0 0
Maribor
Country [128] 0 0
Slovenia
State/province [128] 0 0
Ptuj
Country [129] 0 0
Spain
State/province [129] 0 0
Barcelona
Country [130] 0 0
Spain
State/province [130] 0 0
Bilbao
Country [131] 0 0
Spain
State/province [131] 0 0
Getafe (Madrid)
Country [132] 0 0
Spain
State/province [132] 0 0
Madrid
Country [133] 0 0
Spain
State/province [133] 0 0
Mendaro
Country [134] 0 0
Spain
State/province [134] 0 0
Miranda de Ebro
Country [135] 0 0
Spain
State/province [135] 0 0
San Sebastian de los Reyes
Country [136] 0 0
Spain
State/province [136] 0 0
San Sebastian
Country [137] 0 0
Spain
State/province [137] 0 0
Sevilla
Country [138] 0 0
Spain
State/province [138] 0 0
Vigo
Country [139] 0 0
Sweden
State/province [139] 0 0
Halmstad
Country [140] 0 0
Sweden
State/province [140] 0 0
Lund
Country [141] 0 0
Sweden
State/province [141] 0 0
Norrtalje
Country [142] 0 0
Sweden
State/province [142] 0 0
Stockholm
Country [143] 0 0
Sweden
State/province [143] 0 0
Umea
Country [144] 0 0
Switzerland
State/province [144] 0 0
Baden
Country [145] 0 0
Switzerland
State/province [145] 0 0
Frauenfeld
Country [146] 0 0
Turkey
State/province [146] 0 0
Ankara
Country [147] 0 0
Turkey
State/province [147] 0 0
Izmir
Country [148] 0 0
Turkey
State/province [148] 0 0
Kocaeli
Country [149] 0 0
Turkey
State/province [149] 0 0
Manisa
Country [150] 0 0
Turkey
State/province [150] 0 0
Sivas
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Bristol
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Cambridge
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Cheltenham
Country [154] 0 0
United Kingdom
State/province [154] 0 0
Coventry
Country [155] 0 0
United Kingdom
State/province [155] 0 0
Garston
Country [156] 0 0
United Kingdom
State/province [156] 0 0
Kings Lynn
Country [157] 0 0
United Kingdom
State/province [157] 0 0
London
Country [158] 0 0
United Kingdom
State/province [158] 0 0
Northampton
Country [159] 0 0
United Kingdom
State/province [159] 0 0
Nottingham
Country [160] 0 0
United Kingdom
State/province [160] 0 0
Plymouth
Country [161] 0 0
United Kingdom
State/province [161] 0 0
Taunton
Country [162] 0 0
United Kingdom
State/province [162] 0 0
West Yorkshire

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Astellas Pharma Europe Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study was to see if adding a new type of medication recently approved to treat overactive bladder (mirabegron) to an antimuscarinic treatment (solifenacin) would be more effective in controlling incontinence than when using the antimuscarinic treatment alone.
Trial website
https://clinicaltrials.gov/study/NCT01908829
Trial related presentations / publications
Gibson W, MacDiarmid S, Huang M, Siddiqui E, Stolzel M, Choudhury N, Drake MJ. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus. 2017 Dec;3(6):629-638. doi: 10.1016/j.euf.2017.08.008. Epub 2017 Sep 12.
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stolzel M, Herholdt C, MacDiarmid S; BESIDE study investigators. Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). Eur Urol. 2016 Jul;70(1):136-145. doi: 10.1016/j.eururo.2016.02.030. Epub 2016 Mar 8.
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Study Manager
Address 0 0
Astellas Pharma Europe Ltd.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01908829